A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500774-34-00

Acronym

DC08RUP/1/21

Enrollment

Registered

2022-08-01

Start date

2022-11-08

Completion date

2025-04-09

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis, Urticaria

None listed

Sex/Gender

All

Age

18 Years to No maximum

Portugal, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026